Cargando...
Phase I biomarker modulation study of atorvastatin in women at increased risk for breast cancer
Selective estrogen receptor modulators (SERMs), tamoxifen, and raloxifene that reduce the risk of breast cancer are limited to only estrogen receptor-positive (ER(?)) breast cancer. In addition, patient acceptance of SERMs is low due to toxicity and intolerability. New agents with improved toxicity...
Guardado en:
| Publicado en: | Breast Cancer Res Treat |
|---|---|
| Autores principales: | , , , , , , , , , , , , , , , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
2016
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5989315/ https://ncbi.nlm.nih.gov/pubmed/27287781 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-016-3849-1 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|